Find a Clinical Trial

Showing 81 - 90 of 257 Trials

A phase II study, with a safety lead-in, to evaluate ATX-101, a peptide drug targeting PCNA, in advanced dedifferentiated liposarcoma and leiomyosarcoma

Principal Investigator:

Benjamin Izar, MD

Contact Number:

212-342-5162

NCT Number:

NCT05116683

Population:

Adult

Phase:

II

The purpose of this study is to evaluate the effectiveness of a new investigational drug, ATX-101, for the treatment of dedifferentiated liposarcoma and leiomyosarcoma. ATX-101 is an intravenous (IV) drug which blocks the interaction of a protein called PCNA with a number of “stress response” proteins. These interactions are thought to be important for cancer cell survival and growth. ATX-101 may disrupt these interactions and therefore help treat the cancer. In this study, all patients will receive the same treatment. Most of the exams, tests, and procedures you will have are...
A Phase 2 Multiple Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb®20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT05005728

Population:

Adult

Phase:

II

the purpose of this research study is to determine the safety and tolerability of XmAb20717 by itself and in combination with other anticancer therapies (Olaparib, Cabazitaxel, Docetaxel and Carboplatin). XmAb20717 has not been studied in a significant number of humans, therefore, some of its effects are unknown. XmAb20717 is an investigational antibody drug. An antibody is a kind of protein that your body makes to help fight infections. AmAb20717 is an investigational drug in this study because it has not been approved by the U.S. Food and Drug Administration (FDA), the health authority that...
Audiovisual Didactic Experience for Latino patient treatment Adherence and Non-English speaker Trial Enrollment (ADELANTE) Study in Radiation Oncology

Principal Investigator:

Lisa Ann Kachnic, MD, FASTRO

Contact Number:

212-342-5162

NCT Number:

NCT05351424

Population:

Adult

Phase:

II

In this study, you will be randomized to receive either a brochure or watch a video that discusses radiation and cancer clinical trials. In addition, you will complete questionnaires at seven time points: 1 questionnaire before radiotherapy, 4 questionnaires during the course of radiotherapy and 2 questionnaires at follow-up visits. The questionnaires and brochure or video administration will take place during your standard of care visits. Are you Eligible? (Inclusion Criteria) To be included in the main study, you must: 1. be age 18 years or older 2. be Spanish speaker of Latino Background...
A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6

Principal Investigator:

Benjamin Izar, MD

Contact Number:

212-342-5162

NCT Number:

NCT04830124

Population:

Adult

Phase:

II

The purpose of this study is to test the study drug ALKS 4230 to see how well the drug works on patients with advanced cutaneous melanoma or subjects with advanced muscosal melanoma and have received prior treatment with an anti- programmed death-ligand 1 (anti-PD-[L1]) therapy, and your cancer has spread. This study will explore how well the drug works on your disease and body; also explore potential biomarkers by examining your blood and tissue for genes and proteins that can help identify and/or predict whether a therapy would benefit someone or not. Are you Eligible? (Inclusion Criteria)...
ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies

Principal Investigator:

Ran Reshef, MD

Contact Number:

212-342-5162

NCT Number:

NCT04904588

Population:

Adult

Phase:

II

with a MMUD using stem cells from a donor’s blood [instead of using the donor’s bone marrow]. An allogeneic stem cell transplant is a standard treatment for blood cancers. An allogeneic transplant replaces your abnormal (or diseased) blood cells with healthy blood-making cells from a donor. We’re doing this study to see how well transplant works in adults with a MMUD using stem cells from a donor’s blood. This study treatment does not include any investigational drugs. Are you Eligible? (Inclusion Criteria) Donor: 1. Are you 18 year of age or older and younger then 36...
A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Principal Investigator:

Ran Reshef, MD

Contact Number:

212-342-5162

NCT Number:

NCT05020015

Population:

Adult

Phase:

II

TAK-007 is being developed as a possible treatment for Lymphoma. TAK-007 is a cell therapy, which means that it consists of live cells that have been modified to help your body to fight Lymphoma. The use of TAK-007 in this study is experimental. Fresh (unfrozen) CAR NK cells, similar to TAK-007, are being tested in another study. In this study, frozen TAK-007 cell therapy will be used for the first time in humans. This means that at present there is less information available regarding the safety and ability to treat cancer with this medication in humans. The main purpose of this study is to...
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

Principal Investigator:

Fabio M. Iwamoto, MD

Contact Number:

212-342-5162

NCT Number:

NCT04729959

Population:

Adult

Phase:

II

This study is being done to answer the following question: Can we shrink or stabilize your brain cancer by adding immune therapy drugs to the usual radiation therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your recurrent glioblastoma. The usual approach is defined as care most people get for recurrent glioblastoma. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Have you been diagnosed with glioblastoma that has come back after previous radiation therapy? Are you able to make regularly...
A Phase II Randomized Study of Ibrutinib and Rituximab with or without Venetoclax in Previously Untreated Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Principal Investigator:

Divaya Bhutani, MD

Contact Number:

212-342-5162

NCT Number:

NCT04840602

Population:

Adult

Phase:

II

The purpose of this study is to compare the usual treatment alone to using venetoclax plus the usual treatment. The addition of venetoclax to the usual treatment could shrink the cancer. But, it could also cause side effects. This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking to see if the drug combination of venetoclax with ibrutinib and rituximab shrinks and prevents the return of Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma compared to the usual...
A randomized phase II study of CHO(E)P vs CC-486-CHO(E)P vs duvelisib-CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas

Principal Investigator:

Jennifer Effie Amengual, MD

Contact Number:

212-342-5162

NCT Number:

NCT04803201

Population:

Pediatrics/Adult

Phase:

II

The purpose of this study is to compare the usual treatment alone to using duvelisib or CC-486 plus the usual treatment for patients with peripheral T-cell lymphoma. The usual approach for patients who are not in a study is treatment with the FDA approved chemotherapy regimens used in this trial (CHOP or CHOEP) without the addition of the study drugs duvelisib or CC-486 (azacitidine). The addition of duvelisib or CC-486 (azacitidine) to the usual treatment may or may not increase the chance of cancer going into remission. But, it could also cause side effects, which the study doctors want to...
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)

Principal Investigator:

Joseph G. Jurcic, MD

Contact Number:

212-342-5162

NCT Number:

NCT05143957

Population:

Adult

Phase:

II

You are being asked to participate in this study because you have been diagnosed with Polycythemia Vera (PV) that requires you to have phlebotomies (blood draws from a vein) to control your symptoms. This type of PV is called Phlebotomy- Dependent Polycythemia Vera (PD-PV). This clinical study is testing a new study treatment for this medical condition. The new study treatment is called ISIS 702843 and will be referred to as study drug throughout the rest of this form. All medications, drugs and devices must be approved for use by country regulators such as the U.S. Food and Drug...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages